News
MNPR
0.6550
+0.77%
0.0050
Weekly Report: what happened at MNPR last week (0415-0419)?
Weekly Report · 2d ago
Monopar Announces Radiopharma Presentation Selected For Society Of Nuclear Medicine And Molecular Imaging 2024 Annual Meeting
Monopar Therapeutics Inc. Is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. The company has submitted an abstract to the Society of Nuclear Medicine and Molecular Imaging's 2024 Annual Meeting in Toronto. The abstract is on the preclinical data for its radiopharma program MNPR-101-Zr.
Benzinga · 6d ago
Monopar files patent protecting its MNPR-101 radiopharma optimization findings
Monopar Therapeutics Inc. Files patent protecting its MNPR-101 radiopharma optimization findings. MNPR -3.18% premarket to $0.731. The company has filed a provisional patent application regarding the company's radiopharmaceutical program.
Seeking Alpha · 04/16 12:18
Monopar Therapeutics Advances Radiopharmaceuticals with New Patent
TipRanks · 04/16 12:13
MONOPAR ANNOUNCES FILING OF PATENT PROTECTING MNPR-101 RADIOPHARMA OPTIMIZATION FINDINGS
Reuters · 04/16 12:02
Weekly Report: what happened at MNPR last week (0408-0412)?
Weekly Report · 04/15 11:36
Monopar Therapeutics Price Target Announced at $2.00/Share by JonesTrading
Dow Jones · 04/11 11:50
Monopar Therapeutics Raised to Buy From Hold by JonesTrading
Dow Jones · 04/11 11:50
JonesTrading Upgrades Monopar Therapeutics to Buy, Announces $2 Price Target
Benzinga · 04/11 11:39
MONOPAR THERAPEUTICS INC <MNPR.O>: JONESTRADING RAISES TO BUY
Reuters · 04/11 11:33
Buy Rating on Monopar Therapeutics: Promising Trials and Financial Stability Highlight Growth Potential
TipRanks · 04/11 11:25
Monopar initiates radiopharma phase 1 trial for its advanced cancer treatment
Monopar Therapeutics Inc. Initiates radiopharma phase 1 trial for its advanced cancer treatment. MNPR-101-Zr is a novel radiopharmaceutical imaging agent. The Phase 1 dosimetry trial is now recruiting patients with advanced cancers.
Seeking Alpha · 04/10 12:46
Monopar Therapeutics Begins Phase 1 Cancer Imaging Trial
TipRanks · 04/10 12:12
MONOPAR THERAPEUTICS INC: PHASE 1 DOSIMETRY TRIAL IS EVALUATING SAFETY AND DOSIMETRY OF MNPR-101-ZR IN UP TO 12 PATIENTS WITH ADVANCED CANCER
Reuters · 04/10 12:00
Weekly Report: what happened at MNPR last week (0401-0405)?
Weekly Report · 04/08 11:42
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
NASDAQ · 04/04 13:55
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy
NASDAQ · 04/03 16:00
Weekly Report: what happened at MNPR last week (0325-0329)?
Weekly Report · 04/01 11:38
Monopar Therapeutics GAAP EPS of -$0.12
Seeking Alpha · 03/28 19:26
MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023
Monopar Therapeutics reported earnings per share of -12 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate of -15 cents for Monopar's earnings per cent. The stock was down 1.5% after the report.
Investorplace · 03/28 15:53
More
Webull provides a variety of real-time MNPR stock news. You can receive the latest news about Monopar Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.